Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $105.00 short put and a strike $95.00 long put offers a potential 7.76% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $105.00 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $9.28 would be incurred if the stock dropped below the $95.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 65.13 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Pharmaceutical groups should invest in public health systems
Sun, 11 Aug 2019 11:02:05 +0000
David Ricks writes that “governments face a clear choice. Mr Ricks, chief executive of Eli Lilly and president of the International Federation of Pharmaceutical Manufacturers & Associations, suggests that drug development should be incentivised in the private sector by extending data exclusivity to further encourage pharmaceutical companies to invest in Alzheimer’s research. In the first instance, it is difficult to see how a public health problem is best tackled by keeping intellectual property in the private sector for even longer than is currently the case.
US patients struggle to obtain Eli Lilly’s half-price insulin
Sun, 11 Aug 2019 04:16:21 +0000
US diabetes patients are struggling to obtain Eli Lilly’s half-price insulin, which it unveiled shortly before being grilled by Congress about the soaring price of the essential medicine. Only about 3 per cent of insurance claims for Eli Lilly’s insulin were for the cheaper, generic version Insulin Lispro, compared with 97 per cent for its brand name Humalog, according to recent data from GoodRx, an app that tracks drug prices. Many pharmacists do not know that the cheaper version is available — and other patients cannot access it because their insurance or pharmacy benefit manager has not put it on formulary, the list of drugs that are covered.
Dividend Investors: Don't Be Too Quick To Buy Eli Lilly and Company (NYSE:LLY) For Its Upcoming Dividend
Sat, 10 Aug 2019 12:53:06 +0000
Eli Lilly and Company (NYSE:LLY) is about to trade ex-dividend in the next 3 days. You can purchase shares before the…
Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript
Sat, 10 Aug 2019 00:05:28 +0000
DRNA earnings call for the period ending June 30, 2019.
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
Fri, 09 Aug 2019 16:17:00 +0000
INDIANAPOLIS, Aug. 9, 2019 /PRNewswire/ — Eli Lilly and Company (LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta® (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had stated their intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022. The ruling came in the appeals of U.S. District Court decisions in the cases of Eli Lilly and Company v. Dr. Reddy's Laboratories and Eli Lilly and Company v. Hospira, Inc. Previous rulings in Lilly's favor had precluded the generic companies from launching the alternative salt forms until the patent expires.
Also on Market Tamer…
Follow Us on Facebook